$COLL - On our trading list. A biotech buy for us as this company does make money and just finished buying the Nucynta franchise. EPS estimates have been raised / nice $43 price target.Collegium Pharmaceutical resumed with a Buy at JefferiesJefferies analyst David Steinberg resumed coverage of Collegium Pharmaceutical with a Buy rating and $43 price target post the Nucynta franchise buyout, which he views as "a savvy transaction that significantly improves annual operating cashflow." His 2021 EPS estimate has increased to $4.52 from $2.40 and he thinks further upside could come from off-cycle managed care Xtampza wins and Nucynta gross margin improvement, Steinberg noted. $COLL, Collegium Pharmaceutical, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page